Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H8I3N2O4.Na |
Molecular Weight | 635.8954 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)NC1=C(I)C(C([O-])=O)=C(I)C(NC(C)=O)=C1I
InChI
InChIKey=ZEYOIOAKZLALAP-UHFFFAOYSA-M
InChI=1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1
DescriptionSources: http://www.drugbank.ca/drugs/DB00271Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00271
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety. A commonly used x-ray contrast medium. Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues.
CNS Activity
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=3198373
Curator's Comment: Diatrizoic acid was discovered in 1953 simultaneously and independently by Schering AG in Berlin and by Sterling-Winthrop in the USA.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Cystografin Approved UseRetrograde cystourethrography Launch Date1955 |
|||
Diagnostic | Gastrografin Approved UseGastrografin (DIATRIZOIC ACID) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). Launch Date1958 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.6 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
102 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Transcervical catheterization and cervical patency during the oestrous cycle in domestic cats. | 2001 |
|
The accordion sign at CT: report of a case of Crohn's disease with diffuse colonic involvement. | 2001 |
|
Laparoscopic inflatable band with Roux-en-Y gastric bypass. | 2001 Aug |
|
The role of early radiological studies after gastric bariatric surgery. | 2001 Aug |
|
An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents. | 2001 Dec |
|
Preoperative bowel preparation with meglumine and sodium diatrizoate (Gastrografin): a prospective randomised comparison. | 2001 Dec |
|
Results after colectomy for colonic inertia: a sixteen-year experience. | 2001 Dec |
|
Flow-directed microcatheters for cerebral embolizations using Ethibloc--an in vitro study. | 2001 Dec |
|
Effects of radiographic contrast media on pulmonary vascular resistance of normoxic and chronically hypoxic pulmonary hypertensive rats. | 2001 Dec |
|
Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. | 2001 Dec |
|
Re: Renal artery embolization with diluted hot contrast medium: an experimental study. | 2001 Dec |
|
Diagnostic accuracy of focused appendiceal CT in clinically equivocal cases of acute appendicitis. | 2001 Dec |
|
Glucose alters the susceptibility of mesangial cells to contrast media. | 2001 Jul |
|
Rapid diagnosis of sigmoid volvulus with water soluble urografin in emergency service. | 2001 Nov |
|
Appendiceal disease in women with endometriosis and right lower quadrant pain. | 2001 Nov |
|
Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. | 2001 Nov |
|
Differential effects of radiocontrast agents on human umbilical vein endothelial cells: cytotoxicity and modulators of thrombogenicity. | 2001 Nov 20 |
|
Effect of ionic and nonionic contrast media on fibrinolysis in patients undergoing angiocardiography. | 2001 Oct |
|
Pseudomembranous colitis without diarrhea presenting clinically as acute intestinal pseudo-obstruction. | 2001 Sep |
|
Oesophageal rupture resulting from airbag deployment during a motor vehicle accident. | 2001 Sep |
|
Ionic radiocontrast media disrupt intercellular contacts via an extracellular calcium-independent mechanism. | 2002 |
|
Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. | 2002 Apr |
|
Gastrografin administration in the treatment of postoperative delayed gastric emptying. | 2002 Apr |
|
Effect of iomeprol on rat hippocampal slice synaptic transmission: comparison with other X-ray contrast agents. | 2002 Apr |
|
Thumbprinting due to ischemic colitis in a patient on oral anticoagulation. | 2002 Aug-Sep |
|
Use of near-infrared reflection spectroscopy to study the effects of X-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors. | 2002 Dec |
|
Rectal washout with cytotoxic solution can be extended to the whole colon. | 2002 Dec |
|
Evidence for involvement of mast cell degranulation and subsequent stimulation of histamine H1 and H2 receptors in radiographic contrast media-increased vascular permeability in rats. | 2002 Dec |
|
Primary anastomosis and diverting colostomy in diffuse diverticular peritonitis. | 2002 Feb |
|
Virtual gastroduodenoscopy: a new look at the bypassed stomach and duodenum after laparoscopic Roux-en-Y gastric bypass for morbid obesity. | 2002 Feb |
|
The utility of contrast studies and drains in the management of patients after Roux-en-Y gastric bypass. | 2002 Feb |
|
Systemic platelet effects of contrast media: implications for cardiologic research and clinical practice. | 2002 Jan |
|
Plasma exogenous creatinine clearance test in dogs: comparison with other methods and proposed limited sampling strategy. | 2002 Jan-Feb |
|
Assessment of hypothalamic-pituitary-adrenal axis function after corticosteroid therapy in inflammatory bowel disease. | 2002 Jul |
|
Contrast radiography and intestinal obstruction. | 2002 Jul |
|
Aneurysmal bone cysts: treatment with direct percutaneous Ethibloc injection: long-term results. | 2002 Jul-Aug |
|
Early esophageal transit study after laparoscopic fundoplication: how useful is it? | 2002 Mar |
|
Gastrocolocutaneous Fistula as a complication of peg tube placement. | 2002 Mar |
|
Changes in the fibrinolytic system during angiography with ionic and with nonionic contrast media. | 2002 Mar |
|
Laparoscopic repair for perforated peptic ulcer: a randomized controlled trial. | 2002 Mar |
|
Role of NO in endothelin-regulated drug transport in the renal proximal tubule. | 2002 Mar |
|
Do clinically relevant circulating concentrations of radiographic contrast agents inhibit platelet-dependent arterial thrombosis? | 2002 Mar 1 |
|
New strategies in nonoperative management of meconium ileus. | 2002 May |
|
Renal excretion of ingested gastrografin: clinical relevance in early postoperative treatment of patients who have undergone gastric surgery. | 2002 May |
|
Jejunum free flap in hypopharynx reconstruction: case series. | 2002 May 10 |
|
Safety and efficacy of postoperative continuous positive airway pressure to prevent pulmonary complications after Roux-en-Y gastric bypass. | 2002 May-Jun |
|
The role of theophylline in contrast-induced nephropathy: a case-control study. | 2002 Nov |
|
The value of contrast radiology for postoperative adhesive small bowel obstruction. | 2002 Nov-Dec |
|
Venous port salvage utilizing low dose tPA. | 2002 Nov-Dec |
|
Renal chemoembolization with mitomycin c/Ethibloc: pharmacokinetics and efficacy in an animal model. | 2002 Sep |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: For radiographic examination of segments of the gastrointestinal tract (Gastrografin) oral administration: adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For Enemas or Enterostomy Instillations: should be diluted when it is used for enemas and enterostomy instillations. When used as an enema, the suggested dilution for adults is 240 mL (88 g iodine) in 1,000 mL of tap water. http://www.drugs.com/pro/gastrografin.html
;
The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C390
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
||
|
CFR |
21 CFR 522.563
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Diatrizoate
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
23672589
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
3321
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | RxNorm | ||
|
V5403H8VG7
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
m4263
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID7022912
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
DBSALT000267
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
737-31-5
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
212-004-1
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
SUB10547MIG
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
61815
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
DIATRIZOATE SODIUM
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | Description: A white powder; odourless or almost odourless. Solubility: Freely soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Radiocontrast medium. Storage: Sodium amidotrizoate should be kept in a well-closed container, protected from light. Requirements: Sodium amidotrizoate contains not less than 98.0% and not more than the equivalent of 102.0% of C11H8I3N2NaO4, calculated with reference to the anhydrous substance. | ||
|
V5403H8VG7
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
100000091989
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201220
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
C47981
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
8078
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
358
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
53692
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
24360-64-3
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
ALTERNATIVE |
ACTIVE MOIETY
SUBSTANCE RECORD